NDA 012380 · Parke Davis
Zarontin
Ethosuximide · Oral · Anti-epileptic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1960
Nov 2, 1960
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
3 Phase 3, 2 recruiting
FAERS reports
2,522
2,030 serious, 64 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 25, 2026.
INDICATIONS AND USAGE Zarontin is indicated for the control of absence (petit mal) epilepsy.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 2, 1960 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- ZARONTIN · ETHOSUXIMIDE 250MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethosuximide" as an intervention, any sponsor and status, largest first.
- Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics StudyPivotal-lookingCompleted
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT00088452 · 453 participants · Start Jul 2004 · Primary completion Jan 2013
Drug: Ethosuximide; Lamotrigine and 1 more · For: Childhood Absence Epilepsy; Petit Mal Epilepsy; Epilepsy and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 31 sites in all
- Ethosuximide to Treat IBSPivotal-lookingCompleted
University Hospital, Clermont-FerrandAcademic, hospital or other
NCT02973542 · 162 participants · Start Feb 8, 2018 · Primary completion Mar 7, 2023
Drug: Ethosuximide · For: Irritable Bowel Syndrome
Sites: Clermont-Ferrand, France
- Ketogenic Diet in Infants With Epilepsy (KIWE)Pivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT02205931 · 160 participants (planned) · Start Jan 2015 · Primary completion Jun 2018
Drug: Antiepileptic drug therapy · For: Epilepsy
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 11 sites in all
- Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.Pivotal-lookingCompleted
University Hospital, Clermont-FerrandAcademic, hospital or other
NCT02100046 · 114 participants · Start Mar 2014 · Primary completion Sep 2016
Drug: Zarontin® (ethosuximide) and Stodal® · For: Neuropathic Traumatic Pain; Pain NRS ≥ 4; Peripheral Neuropathic Pain and 1 more
Sites: Clermont-Ferrand, France
- Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic PainStatus unknown
University Hospital, Clermont-FerrandAcademic, hospital or other
NCT04431778 · 64 participants (planned) · Start Nov 1, 2020 · Primary completion Nov 30, 2023
Drug: Ethosuximide; Placebo · For: Peripheral Neuropathic Pain
Sites: Lyon, France; Amiens, France; Annecy, France · 11 sites in all
- Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel SyndromePivotal-lookingRecruiting
Tanta UniversityAcademic, hospital or other
NCT04217733 · 60 participants (planned) · Start Nov 1, 2019 · Primary completion Dec 1, 2030
Drug: pentoxyifylline; Mebeverine and 1 more · For: IBS - Irritable Bowel Syndrome
Sites: Tanta, Egypt
Oslo University HospitalAcademic, hospital or other
NCT00552526 · 60 participants (planned) · Start Nov 2007 · Primary completion Jan 2011
Drug: Antiepileptic drug (AED) · For: Epilepsy; Mental Retardation
Sites: Oslo, Norway
- Ketogenic Diet for New-Onset Absence EpilepsyPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT04274179 · 40 participants (planned) · Start Aug 10, 2020 · Primary completion May 1, 2028
Drug: Absence epilepsy medications · For: Absence Epilepsy; Ketogenic Dieting; Epilepsy, Absence
Sites: Baltimore, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective519
- seizure375
- off label use245
- somnolence162
- generalised tonic-clonic seizure153
- treatment failure121
- petit mal epilepsy120
- drug interaction117
- fatigue113
- epilepsy108
- condition aggravated107
- multiple-drug resistance104
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 37 |
| 2006 | 39 |
| 2007 | 39 |
| 2008 | 51 |
| 2009 | 35 |
| 2010 | 50 |
| 2011 | 51 |
| 2012 | 57 |
| 2013 | 58 |
| 2014 | 54 |
| 2015 | 115 |
| 2016 | 92 |
| 2017 | 106 |
| 2018 | 135 |
| 2019 | 186 |
| 2020 | 175 |
| 2021 | 225 |
| 2022 | 234 |
| 2023 | 215 |
| 2024 | 194 |
| 2025 | 251 |
| 2026 | 107 |
Recalls
1 FDA enforcement reports for this application.
Sep 12, 2019 · Class III · Terminated
Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zarontin (Ethosuximide)
2024 spending
$67K
Beneficiaries
62
298 claims
Per beneficiary
$1,080
$1.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $424,674 |
| 2021 | $427,579 |
| 2022 | $393,866 |
| 2023 | $216,704 |
| 2024 | $66,933 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.
Chu H, Zhang X, Shi J, et al. · J Neurol 2023 · Systematic Review, Network Meta-Analysis
- Ethosuximide dosage regimens.
Buchanan RA, Kinkel AW, Turner JL, et al. · Clin Pharmacol Ther 1976 · Clinical Trial
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Glauser TA, Cnaan A, Shinnar S, et al. · N Engl J Med 2010 · Comparative Study, Multicenter Study
- Metabolism of ethosuximide.
Goulet JR, Kinkel AW, Smith TC · Clin Pharmacol Ther 1976 · Clinical Trial, Controlled Clinical Trial
- Absence seizures in children.
Posner E · BMJ Clin Evid 2013 · Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.